[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100541141":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":31,"locations":40,"responsibleParty":62,"collaborators":26,"id":65,"slug":66,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":26,"eligibilityCriteria":71,"healthyVolunteers":67,"sex":72,"minAge":26,"maxAge":26,"enrollmentInfo":73,"targetDuration":26,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":26,"overallStatus":43,"whyStopped":26,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"Changhai Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"A (COPORT)","ACTIVE_COMPARATOR","COPORT over 7 weeks.",[13],"Radiation: Conventional radiation therapy",{"label":15,"type":16,"description":17,"interventionNames":18},"B（HYPORT）","EXPERIMENTAL","HYPORT over 5 weeks.",[19],"Radiation: Hypofractionated radiation therapy",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"RADIATION","Conventional radiation therapy","66-74 Gy in 33-37 daily fractions of 2 Gy to the prostate bed in the absence of disease progression or unacceptable toxicity.",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Hypofractionated radiation therapy","57.5-65 Gy in 23-26 daily fractions of 2.5 Gy to the prostate bed in the absence of disease progression or unacceptable toxicity.",[15],[32,37],{"name":33,"role":34,"phone":35,"phoneExt":26,"email":36},"Huojun Zhang","CONTACT","021-31162222","huojunzh@163.com",{"name":38,"role":34,"phone":35,"phoneExt":26,"email":39},"Xianzhi Zhao","zhxzh0007@163.com",[41],{"facility":42,"status":43,"city":44,"state":45,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"Changhai hospital","RECRUITING","Shanghai","Shanghai Municipality","200433","China","CN",{"type":50,"coordinates":51},"Point",[52,53],121.45806,31.22222,{"lat":53,"lon":52},[56,60],{"name":57,"role":34,"phone":58,"phoneExt":26,"email":59},"Huojun Zhang, M.D.","+8613311732399","chyyzhj@163.com",{"name":57,"role":61,"phone":26,"phoneExt":26,"email":26},"PRINCIPAL_INVESTIGATOR",{"type":61,"investigatorFullName":63,"investigatorTitle":64,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"Zhang Huo Jun","Director","100541141","hypofractionated-post-prostatectomy-radiotherapy-hyportfor-localized-prostate-cancer-100541141",false,"NCT06325995","Hypofractionated Post-prostatectomy Radiotherapy (HYPORT)for Localized Prostate Cancer","Safety and Efficacy Study of Hypofractionated Post-prostatectomy Radiotherapy (HYPORT)for Localized Prostate Cancer: a Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n* European Cooperative Oncology Group score(ECOG):≤ 2;\n* Patients with pathologically confirmed prostate cancer and completed radical resection of prostate cancer;\n* Postoperative pathological staging of AJCC version 8 pT 3a, pT 3b, pT 4, margin (+), or N1; or serum PSA≥0.1 ng\u002Fml 6 weeks after surgery; or serum PSA \\\u003C0.1 ng\u002Fml 6 weeks after surgery, subsequent follow-up process revealed two consecutive sustained PSA increases (≥0.1 ng \u002F ml) and no clinical imaging (Whole Body Scan (ECT), magnetic resonance imaging (MRI),68Ga PSMA PET \u002F CT, etc.) signs of metastasis;\n* Expected survival time \\>5 years;\n* Patients who voluntarily accept the experimental study protocol after informing the existing treatment options;\n\nExclusion Criteria:\n\n* poor recovery of postoperative urinary control;\n* a previous history of pelvic and abdominal radiotherapy;\n* Participate in other clinical trials that are mutually exclusive with the study intervention within 4 weeks prior to the start of the study;\n* Patients with other malignancies and acute or chronic infections such as human immunodeficiency virus (HIV) (+), hepatitis C virus (HCV) (+) and\u002For positive syphilis;\n* Patients that the investigator considers unsuitable to participate in the clinical trial; patients with other serious systemic diseases, evaluation and compliance of the trial, including severe respiratory, circulatory, neurological, mental, digestive, endocrine, immune, urinary, and other systemic diseases;\n* Patients with contraindications related to radiotherapy;\n* Written informed consent could not be provided, and treatment compliance was poor.Patients unsuitable for participation in this clinical trial as per the judgement of the investigator.","MALE",{"count":74,"type":75},428,"ESTIMATED","INTERVENTIONAL",[78],"NA","The aim of this trial is to compare the safety outcomes of Hypofractionated postprostatectomy radiotherapy (HYPORT) and Conventionally fractionated postprostatectomy radiotherapy(COPORT) in treating patients with localized prostate cancer.\n\nAccumulating evidence has proven the safety and feasibility of HYPORT for localized prostate cancer.But for localized prostate cancer,the optimal dose per fraction of HYPORT is still on its way.\n\nIt is not yet known whether giving HYPORT(57.5-65 Gy in 23-26 daily fractions of 2.5 Gy ) with or COPORT may work better in treating patients with prostate cancer.",[81],"Localized Prostate Cancer","2024-08-22",{"date":84,"type":85},"2024-08-26","ACTUAL",{"date":87,"type":85},"2024-02-01",{"date":89,"type":75},"2031-02-01",{"name":5,"class":6},1]